Targovax submits study protocol for ONCOS-102 to Spanish authorities
Posted: 2 February 2016 | | No comments yet
Targovax has submitted a study protocol to the regulatory authorities in Spain to assess ONCOS-102 in patients with malignant pleural mesothelioma…
Targovax has submitted a study protocol to the regulatory authorities in Spain to assess its ONCOS-102 product in combination with chemotherapy in patients with malignant pleural mesothelioma (MPM).
The company says Spain is expected to become an important country in this study, therefore submission to the competent authorities in Spain is an important step in the clinical development plan.
MPM is a rare type of lung cancer associated with exposure to asbestos. It is highly malignant with a 5-year survival of only 5 to 10%. Most patients are diagnosed too late for surgical intervention for whom standard of care chemotherapy will provide a median overall survival of approximately 1 year.
ONCOS-102 induced TILs in a Phase I study
In a recently completed Phase I study, ONCOS-102 was seen to induce TILs (tumour infiltrating lymphocytes) in 11/12 patients in a mixed population of solid tumors including MPM and detection of tumour specific T-cells in peripheral blood demonstrating systemic and profound immune activation at lesional level.
The study is a randomised phase II study with a Phase Ib safety lead in cohort of 30 patients with first line MPM patients and second line patients who are eligible for treatment with pemetrexed and cisplatin, the standard of care chemotherapy in this indication. The study’s main objectives are determination of safety, immune activation at lesional level and in peripheral blood, clinical response and the correlation between clinical outcome and the immunological activation. Several investigational sites in Europe will participate in this study, which is expected to start during the first half of 2016.
“In this trial, we will study a patient group which is in great need of better therapies. It will also be the first time to assess ONCOS-102 in combination with chemotherapy. As a result, the study will give a better picture of the benefits of Targovax’ immune therapy alongside existing standard of care” says Gunnar Gårdemyr, CEO of Targovax.
ONCOS-102 has orphan drug status in Europe and the USA in MPM.